M2 PRESSWIRE-April 26, 2017-Hemophilia – Market Insights, Epidemiology and Market Forecast – 2023
(C)1994-2017 M2 COMMUNICATIONS
RDATE:26042017
Dublin – Research and Markets has announced the addition of the “Hemophilia – Market Insights, Epidemiology and Market Forecast – 2023” drug pipelines to their offering.
The market size for Hemophilia of 7MM is estimated to grow at CAGR of 6.35% for the forecast period i.e., 2013-2023.
Hemophilia – Market Insights, Epidemiology and Market Forecast-2023-7MM report provides an overview of the disease and global market size of the Hemophilia for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Hemophilia from 2013-2023.
Hemophilia is the most common inherited bleeding disorder which leads to spontaneous bleeding as the blood does not clot properly. Hemophilia is characterized by the spontaneous bleeding and swollen joints due to bleeding into the joints. Hemophilia can be mild, moderate, or severe, depending on amount of clotting factor present in the blood.
Scope:
– The report will help in developing business strategies by understanding the trends shaping and driving the Hemophilia market
– Organize sales and marketing efforts by identifying the best opportunities for Hemophilia in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan
– To understand the future market competition in the 7MM market of Hemophilia and Insightful review of the key market drivers and barriers
– To understand the regulatory scenario in major markets
– The Report also covers the detailed historical and forecasted Hemophilia market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023
Key Topics Covered:
– Hemophilia overview
– Pathophysiology
– Symptoms of disease
– Etiology of disease
– Diagnosis of disease
– Treatment of disease
– Overview of Marketed drugs
– Drug Description
– Mechanism of Action
– Pharmacokinetics Properties
– Marketed Details
– Patent Information
– Patent Exclusivity Expiry Assessment United States (US)
– Patents Details
– Historical and Forecasted sales of marketed molecules in the Global Hemophilia Market
– Global Epidemiology of Hemophilia Forecasted to 2023
– Global Market (2013-2015)
– Global Forecasted Market (2017-2023)
– Global Market by Geography
– Appendix
Companies Mentioned
– Baxalta
– Bayer
– Biogen
– CSL Behring
– Novo Nordisk
– Pfizer
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/9nqjpt/hemophilia